Disease Caused by Rotavirus Infection
Che-Liang Lin 1, §, Shou-Chien Chen 2, 3, §, Shyun-Yeu Liu 4, Kow-Tong Chen*, 5, 6
Identifiers and Pagination:Year: 2014
First Page: 14
Last Page: 19
Publisher Id: TOVJ-8-14
Article History:Received Date: 8/8/2014
Revision Received Date: 28/9/2014
Acceptance Date: 27/10/2014
Electronic publication date: 11 /12/2014
Collection year: 2014
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Although rotavirus vaccines are available, rotaviruses remain the major cause of childhood diarrheal disease worldwide. The Rotarix (GlaxoSmithKline Biologicals Rixensart, Belgium) and RotaTeq (Merck and Co., Inc. Whitehouse Station, New Jersey, USA) vaccines are effective for reducing the morbidity and mortality of rotavirus infection. This article aims to assess the epidemiology of rotaviral gastroenteritis and the efficacy and effectiveness of licensed rotavirus vaccines. This review concludes by presenting challenges in the field that require further exploration by and perspectives from basic and translational research in the future.